TY - JOUR
T1 - Selective inhibitor of endosomal trafficking pathways exploited by multiple toxins and viruses
AU - Gillespie, Eugene J.
AU - Ho, Chi Lee C.
AU - Balaji, Kavitha
AU - Clemens, Daniel L.
AU - Deng, Gang
AU - Wang, Yao E.
AU - Elsaesser, Heidi J.
AU - Tamilselvam, Batcha
AU - Gargi, Amandeep
AU - Dixon, Shandee D.
AU - France, Bryan
AU - Chamberlain, Brian T.
AU - Blanke, Steven R.
AU - Cheng, Genhong
AU - De La Torre, Juan Carlos
AU - Brooks, David G.
AU - Jung, Michael E.
AU - Colicelli, John
AU - Damoiseaux, Robert
AU - Bradley, Kenneth A.
PY - 2013/12/10
Y1 - 2013/12/10
N2 - Pathogenic microorganisms and toxins have evolved a variety of mechanisms to gain access to the host-cell cytosol and thereby exert virulent effects upon the host. One common mechanism of cellular entry requires trafficking to an acidified endosome, which promotes translocation across the host membrane. To identify small-molecule inhibitors that block this process, a library of 30,000 small molecules was screened for inhibitors of anthrax lethal toxin. Here we report that 4-bromobenzaldehyde N-(2,6-dimethylphenyl)semi-carbazone, themost active compound identified in the screen, inhibits intoxication by lethal toxin and blocks the entry ofmultiple other acid-dependent bacterial toxins and viruses into mammalian cells. This compound,whichwe named EGA, also delays lysosomal targeting and degradation of the EGF receptor, indicating that it targets host-membrane trafficking. In contrast, EGA does not block endosomal recycling of transferrin, retrograde traf fi cking of ricin, phagolysosomal trafficking, or phagosome permeabilization by Franciscella tularensis. Furthermore, EGA does not neutralize acidic organelles, demonstrating that its mechanism of action is distinct from pH-raising agents such as ammonium chloride and bafilomycin A1. EGA is a powerful tool for the study of membrane trafficking and represents a class of host-targeted compounds for therapeutic development to treat infectious disease.
AB - Pathogenic microorganisms and toxins have evolved a variety of mechanisms to gain access to the host-cell cytosol and thereby exert virulent effects upon the host. One common mechanism of cellular entry requires trafficking to an acidified endosome, which promotes translocation across the host membrane. To identify small-molecule inhibitors that block this process, a library of 30,000 small molecules was screened for inhibitors of anthrax lethal toxin. Here we report that 4-bromobenzaldehyde N-(2,6-dimethylphenyl)semi-carbazone, themost active compound identified in the screen, inhibits intoxication by lethal toxin and blocks the entry ofmultiple other acid-dependent bacterial toxins and viruses into mammalian cells. This compound,whichwe named EGA, also delays lysosomal targeting and degradation of the EGF receptor, indicating that it targets host-membrane trafficking. In contrast, EGA does not block endosomal recycling of transferrin, retrograde traf fi cking of ricin, phagolysosomal trafficking, or phagosome permeabilization by Franciscella tularensis. Furthermore, EGA does not neutralize acidic organelles, demonstrating that its mechanism of action is distinct from pH-raising agents such as ammonium chloride and bafilomycin A1. EGA is a powerful tool for the study of membrane trafficking and represents a class of host-targeted compounds for therapeutic development to treat infectious disease.
UR - http://www.scopus.com/inward/record.url?scp=84890278211&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84890278211&partnerID=8YFLogxK
U2 - 10.1073/pnas.1302334110
DO - 10.1073/pnas.1302334110
M3 - Article
AN - SCOPUS:84890278211
SN - 0027-8424
VL - 110
SP - E4904-E4912
JO - Proceedings of the National Academy of Sciences of the United States of America
JF - Proceedings of the National Academy of Sciences of the United States of America
IS - 50
ER -